A Phase II Study of Belinostat and ASTX727 to Treat Inoperable or Metastatic Conventional Chondrosarcoma

Share
Print

Full Title

A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (NCI 10330) (CIRB)

Purpose

The purpose of this study is to assess the safety and effectiveness of combining belinostat with ASTX727 to treat conventional chondrosarcoma that is inoperable or metastatic. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving belinostat in combination with the chemotherapy drug ASTX727 may lower the chance that inoperable and metastatic chondrosarcoma will grow or spread.

Participants in this study will receive belinostat with ASTX727. Belinostat is given intravenously (by vein) and ASTX727 is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic chondrosarcoma.
  • Patients who received previous treatments must recover from the serious side effects of those therapies before receiving the study treatment.
  • Participants must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Mrinal Gounder at 646-888-4167.

Protocol

21-365

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators